A carregar...
Mitochondrial Complex I Inhibitor Deguelin induces metabolic reprogramming and sensitizes vemurafenib resistant BRAF(V600E) mutation bearing metastatic melanoma cells.
Treatment with vemurafenib, a potent and selective inhibitor of MAPK signaling downstream of the BRAF(V600E) oncogene, elicits dramatic clinical responses in patients with metastatic melanoma. Unfortunately, the clinical utility of this drug is limited by a high incidence of drug resistance. Thus, t...
Na minha lista:
| Publicado no: | Mol Carcinog |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6692247/ https://ncbi.nlm.nih.gov/pubmed/31211467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mc.23068 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|